NeuroPace, Inc. NPCE
14.06
0.09
0.64%
as of 25 Sep
- Market cap
- $479.5M
- P/E
- 0.0×
Follow NPCE
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(169.27%) | (158.74%) | (111.38%) | (122.05%) | |
| (23.57%) | (21.44%) | (20.63%) | (18.82%) | ||
ROIC |
(70.97%) | (60.58%) | (53.73%) | (44.64%) | |
Return on Tangible Assets |
(31.22%) | (27.74%) | (29.91%) | (27.30%) | |
Average Days of Receivables |
60.02 | 47.22 | 54.23 | 52.98 | |
Free Cash Flow per Share |
(0.50) | (0.35) | (0.29) | (0.34) | |
Free Cash Flow |
(16.58) | (11.34) | (9.84) | (11.61) | |
Capital Expenditures |
(0.27) | (0.33) | (0.41) | (0.37) | |
Piotroski F-Score |
5.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(11.88%) | (7.92%) | (7.39%) | (9.17%) | |
Accounts Receivable Turnover |
6.86 | 7.75 | 6.59 | 7.22 | |
Accounts Payable Turnover |
5.91 | 9.63 | 5.05 | 4.98 | |
Inventory Turnover |
1.32 | 1.61 | 1.43 | 1.29 | |
Average Days of Payables |
84.04 | 28.47 | 76.23 | 69.01 | |
Days of Inventory on Hand |
332.06 | 238.28 | 282.05 | 297.29 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
29.62% | 27.89% | 27.77% | 26.92% | |
Selling, General and Administrative Expense of Revenue |
70.00% | 65.68% | 67.36% | 64.79% | |
Share Based Compensation of Revenue |
12.20% | 11.09% | 10.79% | 9.54% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.51 | 0.44 | 0.59 | |
Depreciation/Fixed assets |
1.80 | 1.94 | 1.76 | 1.87 | |
Capex/Depreciation |
(0.14) | (0.15) | (0.18) | (0.16) | |
Revenue per Share |
2.74 | 3.06 | 2.95 | 3.02 | |
Operating CF per Share |
(0.49) | (0.34) | (0.28) | (0.33) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(26.40%) | (21.47%) | (21.67%) | (18.58%) |
Columns are period end dates